The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study

Annals of the Rheumatic Diseases

Volumn 66, Issue 8, 2007, Pages 1038-1042

  Heiberg, Marte Schrumpf ^a   Kaufmann, C ^b   Rodevand E ^c   Mikkelsen, K ^d   Koldingsnes, W ^e   Mowinckel, P ^a   Kvien, T K ^a  

^a DIAKONHJEMMET HOSPITAL   (Norway)

^b Buskerud Central Hospital   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d Hospital for Rheumatic Diseases   (Norway)

^e UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE;

ADULT; ALLERGIC REACTION; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE ACTIVITY; DRUG EFFICACY; DRUG RESEARCH; DYSPNEA; FEMALE; FEVER; HEADACHE; HUMAN; INFLUENZA; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RASH; RESPIRATORY TRACT INFECTION; SCORING SYSTEM; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; JOINTS; LOGISTIC MODELS; MALE; METHOTREXATE; MIDDLE AGED; NORWAY; PAIN; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34547195862     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.064808     Document Type: Article

References (26)

1. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(Suppl 2):ii14-17.
2. Madland TM, Apalset EM, Johannessen AE, Rossebo B, Brun JG. Prevalence, disease manifestations, and treatment of psoriatic arthritis in western Norway. J Rheumatol 2005;32(10):1918-22.
3. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits or infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005;52(4):1227-36.
4. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50(7):2264-72.
5. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52(10):3279-89.
6. Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 2005;64(Suppl 2):ii74-7.
7. Black RL, O'Brien WM, Vanscott EJ, Auerbach R, Eisen AZ, Bunim JJ. Methotrexate therapy in psoriatic arthritis; double-blind study on 21 patients. JAMA 1964;189:743-7.
8. Willkens RF, Williams HJ, Ward JR, Egger MJ, Reading JC, Clements PJ, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984;27(4):376-81.
9. Kvien TK, Mikkelsen K, Nordvag BY. Results from controlled clinical trials: how relevant for clinical practice? J Rheumatol 2003;30(6):1135-7.
10. Wolfe F, Michaud K, Dewitt EM. Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues. Ann Rheum Dis 2004;63(Suppl 2):ii13-7.
11. Bombardier C, Maetzel A. Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies? Ann Rheum Dis 1999;58(Suppl 1):182-5.
12. Kvien TK, Heiberg, Lie E, Kaufmann C, Mikkelsen K, Nordvag BY, et al. A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. Clin Exp Rheumatol 2005;23(5)(Suppl 39):S188-94.
13. Fransen J, Antoni C, Mease PJ, Uter W, Kavanaugh A, Kalden JR, et al. Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: Analysis of data from randomized, controlled trials of two TNF inhibitors. Ann Rheum Dis. Published Online First: 27 April 2006, doi:10.1136/ard.2006.051706..
14. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: Dimensions and Practical Applications. Health Qual Life Outcomes 2003;1(1):20.
15. Gladman DD, Mease PJ, Krueger G, van der Heidje DM, Antoni C, Helliwell PS, et al. Outcome measures in psoriatic arthritis. J Rheumatol 2005;32(11):2262-9.
16. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983;26(11):1346-53.
17. McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994;32(1):40-66.
18. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21(2):271-92.
19. Kleinbaum DG. Applied regression analysis and other multivariate methods. Boston: PWS-Kent Pubulishing Company, 1988.
20. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Statist Med. Published Online First: 17 May 2006, doi:10.1002/sim, 2580.
21. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64(8):1150-7.
22. Kavanaugh A, Antoni C, Krueger GG, Yan S, Bala M, Dooley LT, et al. Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis 2006;65(4):471-7.
23. Bansback NJ, Ara R, Barkham N, Brennan A, Fraser AD, Conway P, et al. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. Rheumatology (Oxford) 2006;45(8):1029-38.
24. Brazier J, Roberts J, Tsuchiya A, Busschbach J. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 2004;13(9):873-84.
25. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7(4):R796-R806.
26. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003;42(2):244-57.